US Fusion Biopsy Market (2024-2029)
The US Fusion Biopsy Market was valued at $114.3 Million in 2024 and projected to reach to $163 Million by 2029, representing a compound annual growth rate of 7.4%. The US fusion biopsy market is poised for sustained growth through 2029, driven by increasing clinical adoption, technological advancements, and strong healthcare infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Fusion Biopsy Market Trends and Insights
- This growth in the US reflects increasing adoption of advanced imaging-guided biopsy technologies across major healthcare systems and diagnostic centers.
- The US market benefits from high healthcare spending, strong reimbursement frameworks, and widespread availability of sophisticated medical infrastructure that supports fusion biopsy procedures. In the US, fusion biopsy adoption is driven by rising demand for minimally invasive diagnostic procedures and improved accuracy in tissue sampling.
- The US healthcare sector's emphasis on precision medicine and early disease detection continues to fuel market expansion through 2029.
- Key US medical institutions and private diagnostic networks are increasingly integrating fusion biopsy platforms into their oncology and urology departments, positioning the US as a leading market for this technology..
Key Market Statistics
- CAGR (2024-2029) 7.4% CAGR
- Market Size, 2024 ~USD 114.3 Million
- Forecast, 2029 ~USD 163 Million
- Country US
US Fusion Biopsy Market Overview
Market Valuation :
The US fusion biopsy market reached $114.3 million in 2024, driven by widespread adoption of advanced imaging-guided technologies across major US healthcare systems and diagnostic centers.
Strong Growth Trajectory :
With a CAGR of 7.4% through 2029, the US market is expanding faster than the global average of 7.1%, reflecting robust demand for precision diagnostic solutions in American healthcare.
Reimbursement Advantage :
The US market benefits from favorable reimbursement policies and high healthcare spending, enabling hospitals and diagnostic centers to invest in cutting-edge fusion biopsy technologies.
Technology Adoption :
Major US healthcare systems are increasingly integrating fusion biopsy platforms into their diagnostic workflows, improving accuracy and patient outcomes in cancer detection and tissue sampling.
US Fusion Biopsy Market Dynamics
- Rising demand for minimally invasive diagnostic procedures and improved reimbursement coverage will accelerate market expansion across major metropolitan healthcare networks and regional diagnostic centers.
- The US market's growth outpacing global trends reflects the country's commitment to precision medicine and advanced diagnostic capabilities.
- Continued investment in imaging-guided biopsy systems by leading healthcare providers will further strengthen market penetration and establish fusion biopsy as a standard diagnostic modality across oncology and interventional radiology departments..
Related Ecosystem
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- The US fusion biopsy market is valued at $114.3 million in 2024 and will reach $163.0 million by 2029 at a 7.4% CAGR.
- The US market is driven by high healthcare expenditure, favorable reimbursement policies, and advanced medical infrastructure supporting minimally invasive procedures.
- US adoption is accelerated by demand for precision diagnostics and early disease detection in oncology and urology specialties.
- The US represents a mature, high-growth market with strong institutional investment in fusion biopsy technology platforms.
Fusion Biopsy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | TRANSPERINEAL (Route Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 7.1% from 2024 to 2029 |
| Largest Segment | PROSTATE CANCER (Application) |
| Market Size Base Year (Billions) | ~USD 0.65 (2024) |
| Revenue Forecast (Billions) | ~USD 0.91 (2029) |
| Segments Covered | Route Type, Application, Product, End User |
US Fusion Biopsy Market Report Segmentation
4 segment dimensions are covered across the global market.
By Route Type
- Other Route Types
- Other Routes
- Transperineal
- Transrectal
By Application
- Other Applications
- Prostate Cancer
By Product
- Consumables
- Equipment
By End User
- Hospitals
- Other End Users
US: FUSION BIOPSY MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 95.9 | 102.6 | 110 | 118.4 | 128 | 138.6 | 150.6 | 164.4 | 8.4 |
| OTHER END USERS | 65.8 | 69.3 | 73 | 77.3 | 82.2 | 87.5 | 93.6 | 100.5 | 6.6 |
| TOTAL | 161.7 | 171.9 | 183 | 195.8 | 210.1 | 226.1 | 244.2 | 264.9 | 7.7 |
Target Audience
- Medical Device Manufacturers : Need US-specific market data to guide product development, regulatory strategy, and commercial launch planning for fusion biopsy systems in the American healthcare market.
- Healthcare System Executives : Require market insights to justify capital investments in fusion biopsy technology, evaluate vendor options, and plan diagnostic center upgrades across US hospital networks.
- Investment & Private Equity Firms : Seek detailed US market analysis to identify acquisition targets, assess growth potential, and make informed investment decisions in diagnostic imaging and biopsy technology companies.
- Diagnostic Center Operators : Need US market trends and reimbursement data to optimize service offerings, justify technology investments, and remain competitive in precision diagnostic services.
- Healthcare Consultants & Analysts : Require comprehensive US market intelligence to support client advisory work, competitive benchmarking, and strategic recommendations in diagnostic imaging and oncology services.
Reasons to Buy this Report
- Market Size & Forecast Data : Access precise US market valuations ($114.3M in 2024, $163.0M in 2029) with detailed CAGR analysis to benchmark competitive positioning and investment decisions.
- Regional Growth Insights : Understand US-specific growth drivers including reimbursement policies, healthcare spending patterns, and technology adoption rates that differ from global markets.
- Strategic Planning : Leverage US market intelligence to develop targeted go-to-market strategies, identify high-growth segments, and prioritize healthcare system partnerships.
- Competitive Landscape : Gain actionable insights into US market dynamics, key players, and adoption trends to inform product development and market entry strategies.
- Investment Justification : Support capital allocation decisions with comprehensive US market data demonstrating strong growth potential and favorable reimbursement environment for fusion biopsy technologies.
Frequently asked questions
What is the current size of the US fusion biopsy market?
The US fusion biopsy market was valued at $114.3 million in 2024 and is expected to grow to $163.0 million by 2029.
What is the growth rate of the US fusion biopsy market?
The US fusion biopsy market is growing at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2029.
What factors are driving growth in the US fusion biopsy market?
Growth in the US is driven by increasing adoption of minimally invasive diagnostic procedures, strong reimbursement frameworks, high healthcare spending, and demand for precision medicine in oncology and urology.
Which medical specialties are adopting fusion biopsy most in the US?
Oncology and urology departments in US medical institutions are leading the adoption of fusion biopsy technology for improved diagnostic accuracy.
How does the US fusion biopsy market compare to other regions?
The US represents a mature, high-growth market with advanced healthcare infrastructure and strong institutional investment, positioning it as a leading global market for fusion biopsy technology.
RESEARCH METHODOLOGY
To determine the current size of the fusion biopsy market, this study engaged in four main activities. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, assumptions, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.
The four steps involved in estimating the market size are
Secondary Research
Within the secondary data collection process, a range of secondary sources were reviewed so as to identify and gather data for this study, including regulatory bodies, databases (like D&B Hoovers, Bloomberg Business, and Factiva), white papers, certified publications, articles by well-known authors, annual reports, press releases, and investor presentations of companies.
Primary Research
In the primary research phase, a comprehensive approach was employed, involving the interviewing of several sources from both the supply and demand sides. The purpose of these interviews was to obtain the quantitative and qualitative information needed to put up this report. The main sources of information were industry experts from both core and related sectors, as well as preferred manufacturers, distributors, suppliers, pioneers in technology, and organizations involved in every aspect of this industry's value chain. A variety of primary respondents, including important industry stakeholders, subject-matter experts, C-level executives from crucial market companies, and industry advisers, were carefully questioned in-depth. The goal was to gather and validate important qualitative and quantitative insights and to conduct a thorough assessment of future possibilities.
A breakdown of the primary respondents is provided below:
Note 1: Others include sales, marketing, and product managers.
Note 2: Tiers of companies are defined based on their total revenue. As of 2023, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION | |
|---|---|---|
| GE Healthcare | Business Manager | |
| Koninklijke Philips N.V. | Marketing Manger | |
| FUJIFILM Corporation | Consultant | |
Market Size Estimation
All major product providers offering various products and services were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of the fusion biopsy market was also split into various segments and subsegments at the region and country level based on:
- Offering mapping of various manufacturers for each type in the fusion biopsy market at the regional and country-level
- Relative adoption pattern of fusion biopsy market among key application segments at the regional and/or country-level
- Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
- Detailed secondary research to gauge the prevailing market trends at the regional and/or country level
Both top-down and bottom-up approaches were used to estimate and validate the total size of fusion biopsy market.
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. By examining a number of variables and patterns from the supply and demand sides, the data was triangulated.
Market Definition
A fusion biopsy device is an advanced diagnostic tool that combines MRI and ultrasound imaging to create a detailed 3D visualization of the prostate. This device enables precise identification of abnormal tissue areas, enhancing the accuracy of biopsy procedures by guiding the needle directly to the targeted regions.
Stakeholders
- Fusion biopsy system manufacturers and distributors
- Hospitals
- Ambulatory Surgery Centers
- Cancer Centers
- Surgeons and Medical Staff
- Urologists
- Selected Radiologists
- Healthcare Providers
- Market Research and Consulting Firms
- Government Associations
- Venture Capitalists and Investors
Report Objectives
- To define, describe, segment, and forecast the fusion biopsy market by route type, product, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To assess the fusion biopsy market with respect to Porter’s five forces, regulatory landscape, the value chain, the supply chain, ecosystem analysis, patent protection, pricing assessment, key stakeholders, and buying criteria
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall fusion biopsy market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to six regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches, collaborations, and other developments
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Get the Full Fusion Biopsy Market Report
Full forecast, segment splits, and company analysis for all Fusion Biopsy Market.
- Canada Fusion Biopsy Market
- Germany Fusion Biopsy Market
- UK Fusion Biopsy Market
- France Fusion Biopsy Market
- Italy Fusion Biopsy Market
- Spain Fusion Biopsy Market
- China Fusion Biopsy Market
- Japan Fusion Biopsy Market
- India Fusion Biopsy Market
- Rest Of Europe Fusion Biopsy Market
- Rest Of Asia Pacific Fusion Biopsy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
